[go: up one dir, main page]

WO2025234773A1 - Composition pour améliorer la mémoire et prévenir, soulager ou traiter une déficience cognitive, contenant un extrait de galium odoratum en tant que principe actif - Google Patents

Composition pour améliorer la mémoire et prévenir, soulager ou traiter une déficience cognitive, contenant un extrait de galium odoratum en tant que principe actif

Info

Publication number
WO2025234773A1
WO2025234773A1 PCT/KR2025/006160 KR2025006160W WO2025234773A1 WO 2025234773 A1 WO2025234773 A1 WO 2025234773A1 KR 2025006160 W KR2025006160 W KR 2025006160W WO 2025234773 A1 WO2025234773 A1 WO 2025234773A1
Authority
WO
WIPO (PCT)
Prior art keywords
extract
composition
preventing
active ingredient
cognitive dysfunction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/KR2025/006160
Other languages
English (en)
Korean (ko)
Inventor
고영훈
박맑은
최장기
이위
양혜진
김부윤
권은빈
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Korea Institute of Oriental Medicine KIOM
Original Assignee
Korea Institute of Oriental Medicine KIOM
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Korea Institute of Oriental Medicine KIOM filed Critical Korea Institute of Oriental Medicine KIOM
Publication of WO2025234773A1 publication Critical patent/WO2025234773A1/fr
Pending legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/74—Rubiaceae (Madder family)
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K10/00—Animal feeding-stuffs
    • A23K10/30—Animal feeding-stuffs from material of plant origin, e.g. roots, seeds or hay; from material of fungal origin, e.g. mushrooms
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/322—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the nervous system or on mental function

Definitions

  • the present invention relates to a composition for improving memory and preventing, improving or treating cognitive dysfunction, comprising a sagebrush extract as an active ingredient.
  • Cognitive impairment is the most common symptom and occurs in the early stages of Alzheimer's disease or dementia. Patients with early-stage Alzheimer's disease experience recent memory impairment, which is an inability to recall the details of recent conversations or events. This is due to damage to the neurons in the hippocampus, which reduces the ability to store recent memories. During this stage, remote long-term memory for events in the distant past is relatively well maintained.
  • Dementia is generally a complex clinical syndrome that shows distinct impairments in human cognitive function, intellectual ability, emotion, and behavioral changes, and it is a condition in which the cerebral cortex dysfunction such as memory, attention, language function, and visuospatial ability occurs, causing great difficulty in carrying out daily social life.
  • dementia refers to a case in which one or more cognitive functions, including memory, are impaired, and simple memory decline is not considered dementia.
  • dementia causes of dementia are diverse, including degenerative brain diseases such as Alzheimer's Disease and Parkinson's Disease, cerebral hemorrhage, metabolic diseases such as hepatic encephalopathy and Wilson's Disease, infectious diseases such as neurosyphilis, acquired immunodeficiency syndrome, drug addiction such as alcohol, or brain trauma.
  • diseases that can cause structural or functional abnormalities in the central nervous system can cause dementia.
  • dementia caused by Alzheimer's Disease is the most common, accounting for 50-60%, followed by dementia caused by cerebrovascular disease.
  • Methods for improving or preventing memory loss include surgical treatment, medication, or the use of functional substances. Because surgical treatment is not readily available, for diseases that impair memory, such as dementia, preventative measures are recommended, focusing on the continuous intake of medications or functional substances that improve or mitigate memory loss, rather than post-onset treatments. Therefore, there is a growing need to develop safe, side-effect-free, and consistently ingestible natural substances that can improve learning or memory.
  • Galium odoratum is a perennial herb that grows in high mountain forests. Its stem is erect, square, and grows to a height of 25–40 cm. Its leaves are whorled in groups of 6–10, 2.5–4 cm long and 0.5–1 cm wide, with upward-facing hairs on the central vein and margins. A single vertical vein is distinct. It has no petioles. The flowers, which bloom from April to June and are borne in cymes at the ends of the stems, are white and 4–5 mm in diameter. The corolla is funnel-shaped and divided into four lobes. The fruit is a round, sessile pod covered with numerous hook-like hairs.
  • Galium odoratum has funnel-shaped flowers and a distinct corolla tube, making it distinct from other members of the genus Galium.
  • the leaves of the dog's paw are arranged in whorls of 4 to 8, and the three vertical veins on the leaf blade are distinct, making it different. It is also called the dog's paw.
  • a composition for preventing or improving atopic dermatitis containing a sedge extract as an active ingredient is disclosed in Korean Patent Publication No. 2016-0159344, and a food composition for improving intestinal function containing an extract of Palseoncho is disclosed in Korean Patent Publication No. 2024-0012201.
  • a composition for improving memory and preventing, improving, or treating cognitive dysfunction containing the sedge extract of the present invention as an active ingredient has not yet been disclosed.
  • the present invention was derived from the above-mentioned needs, and the present invention provides a composition for improving memory and preventing, improving or treating cognitive dysfunction, which contains a sedge extract as an active ingredient, and the sedge extract has an excellent neuronal cell protection effect, and has been confirmed to have an effect of improving memory and enhancing cognitive function in a Y maze experiment using an animal model with impaired cognitive function, thereby completing the present invention.
  • the present invention provides a pharmaceutical composition for preventing or treating cognitive dysfunction containing an extract of Galium odoratum as an effective ingredient.
  • the present invention provides a health functional food composition for improving learning ability or memory, containing an extract of Galium odoratum as an active ingredient.
  • the present invention provides a feed additive for improving memory containing an extract of Galium odoratum as an effective ingredient.
  • the present invention provides a herbal medicine composition for preventing or treating cognitive dysfunction containing an extract of Galium odoratum as an active ingredient.
  • the present invention provides a veterinary composition for preventing or treating cognitive dysfunction containing an extract of Galium odoratum as an active ingredient.
  • the present invention relates to a composition for improving memory and preventing, improving or treating cognitive dysfunction, comprising a sedge extract as an active ingredient.
  • the sedge extract of the present invention has an excellent neuronal cell protection effect and, in a Y-maze experiment using an animal model with impaired cognitive function, has the effect of improving memory and enhancing cognitive function.
  • Figure 1 shows the results of confirming the neuroprotective effect of the ethanol extract of the schisandra chinensis by co-treating glutamate and the ethanol extract of the schisandra chinensis in mouse-derived hippocampal neurons.
  • ### indicates that the cell viability of the glutamate-treated group (-) was statistically significantly decreased compared to the normal group (Con), and p ⁇ 0.001, and * and *** indicate that the cell viability of the group simultaneously treated with glutamate and 5-100 ⁇ g/ml of the ethanol extract of the schisandra chinensis was statistically significantly increased compared to the glutamate-treated group (-), and * indicates p ⁇ 0.05, and *** indicates p ⁇ 0.001.
  • Figure 2 shows the results of confirming the neuroprotective effect of the schizont water extract by co-treating glutamate and schizont water extract in mouse-derived hippocampal neurons.
  • ### indicates that the cell viability of the glutamate treatment group (-) was statistically significantly decreased compared to the normal group (Con), and p ⁇ 0.001, and * and *** indicate that the cell viability of the group simultaneously treated with glutamate and 10-50 ⁇ g/ml schizont water extract was statistically significantly increased compared to the glutamate treatment group (-), and * indicates p ⁇ 0.05, and *** indicates p ⁇ 0.001.
  • Figure 3 shows the results of the time spent in a new space in a Y-maze space that confirmed the cognitive function-improving effects of ethanol (GO-E) and hot water (GO-W) extracts of sedge in a scopolamine-induced cognitive impairment animal model.
  • CON is the normal control group
  • SCO is the scopolamine-administered group
  • SCO+GO-E50 is the group administered scopolamine and 50 mg/kg of ethanol extract of sedge
  • SCO+GO-W50 is the group administered scopolamine and 50 mg/kg of water extract of sedge
  • SCO+Done is the group administered scopolamine and donepezil.
  • Figure 4 shows the results of the alternation ratio for three arms in a Y-maze space that confirmed the cognitive function-improving effects of ethanol (GO-E) and hot water (GO-W) extracts of sedge in a scopolamine-induced cognitive impairment animal model.
  • CON is the normal control group
  • SCO is the scopolamine-administered group
  • SCO+GO-E50 is the group administered scopolamine and 50 mg/kg of ethanol extract of sedge
  • SCO+GO-W50 is the group administered scopolamine and 50 mg/kg of water extract of sedge
  • SCO+Done is the group administered scopolamine and donepezil.
  • the present invention relates to a pharmaceutical composition for preventing or treating cognitive dysfunction containing an extract of Galium odoratum as an active ingredient.
  • the above-mentioned extract of the sedge may be prepared by a method including, but not limited to, the following steps:
  • step (3) A step of producing an extract by concentrating and drying the filtered extract of step (2) under reduced pressure.
  • the extraction solvent is preferably water, a lower alcohol of C 1 to C 4 or a mixture thereof, more preferably ethanol or water, and even more preferably water, but is not limited thereto.
  • the extraction of the snail shell may utilize any conventional method known in the art, such as filtration, hot water extraction, immersion extraction, reflux cooling extraction, and ultrasonic extraction.
  • the reduced pressure concentration in step (3) is preferably performed using a vacuum reduced pressure concentrator or a vacuum rotary evaporator, but is not limited thereto.
  • the drying is preferably performed using reduced pressure drying, vacuum drying, boiling drying, spray drying, or freeze drying, but is not limited thereto.
  • the above cognitive dysfunction is preferably one selected from among amnesia, Binswanger's disease, learning disorder, mild cognitive impairment, agnosia, aphasia, apraxia, and delirium, but is not limited thereto.
  • composition of the present invention is preferably prepared in any one formulation selected from among capsules, powders, granules, tablets, suspensions, emulsions, syrups, and aerosols, but is not limited thereto.
  • composition of the present invention may further include a pharmaceutically acceptable carrier, excipient, or diluent in addition to the above-mentioned effective ingredient, and may be in various oral or parenteral dosage forms.
  • a pharmaceutically acceptable carrier such as commonly used fillers, bulking agents, binders, wetting agents, disintegrants, and surfactants.
  • Solid preparations for oral administration include capsules, powders, granules, tablets, pills, etc., and these solid preparations are prepared by mixing one or more compounds with at least one excipient, such as starch, calcium carbonate, sucrose, lactose, gelatin, etc.
  • Liquid preparations for oral administration include suspensions, emulsions, syrups, and aerosols.
  • simple diluents such as water and liquid paraffin, they may contain various excipients such as wetting agents, sweeteners, fragrances, and preservatives.
  • Preparations for parenteral administration include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilizers, and suppositories.
  • Non-aqueous solvents and suspending agents can be propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable esters such as ethyl oleate.
  • Suppository bases can include witepsol, macrogol, Tween 61, cacao butter, laurin butter, and glycerogelatin.
  • a method such as topical application to the skin or intraperitoneal, rectal, intravenous, intramuscular, subcutaneous, intrauterine, epidural, or intracerebrovascular injection.
  • composition according to the present invention is administered in a pharmaceutically effective amount.
  • pharmaceutically effective amount means an amount sufficient to treat a disease with a reasonable benefit/risk ratio applicable to medical treatment.
  • the level of the effective amount may be determined based on factors including the type and severity of the patient's disease, the activity and sensitivity of the drug to the drug, the time of administration, the route of administration and excretion rate, the duration of treatment, concurrently used drugs, and other factors well known in the medical field.
  • the composition of the present invention may be administered as an individual therapeutic agent or in combination with other therapeutic agents, may be administered sequentially or simultaneously with conventional therapeutic agents, and may be administered singly or in multiple doses. It is important to take all of the above factors into consideration and administer an amount that achieves the maximum effect with the minimum amount without causing side effects, and this can be easily determined by those skilled in the art.
  • the dosage of the composition of the present invention varies depending on the patient's weight, age, sex, health condition, diet, administration time, administration method, excretion rate, and disease severity, and the daily dosage is 0.01 to 2,000 mg/kg based on the amount of the extract of the schisandra chinensis, preferably 30 to 500 mg/kg, and more preferably 50 to 300 mg/kg, and can be administered 1 to 6 times a day.
  • the composition of the present invention can be used alone or in combination with methods using surgery, radiation therapy, hormone therapy, chemotherapy, and biological response modifiers.
  • the present invention relates to a health functional food composition for improving learning ability or memory containing an extract of Galium odoratum as an active ingredient.
  • the above health functional food composition may be manufactured in any one formulation selected from powder, granules, pills, tablets, capsules, candy, syrup, and beverage, but is not limited thereto.
  • the effective ingredient may be added as is or used together with other foods or food ingredients, and may be used appropriately according to a conventional method.
  • the effective ingredient may be used appropriately depending on its intended use (prevention, health, or therapeutic treatment).
  • the composition of the present invention is added in an amount of 15 parts by weight or less, preferably 10 parts by weight or less, based on the raw material.
  • the amount may be below the above range, and since there is no problem in terms of safety, the effective ingredient may also be used in an amount exceeding the above range.
  • Examples of foods to which the above health functional food composition can be added include meat, sausage, bread, chocolate, candy, snacks, confectionery, pizza, ramen, other noodles, gum, dairy products including ice cream, various soups, beverages, tea, drinks, alcoholic beverages, and vitamin complexes, and include all health functional foods in the conventional sense.
  • the health functional food composition of the present invention can be manufactured into a food, particularly a functional food.
  • the functional food of the present invention can include commonly added ingredients. For example, it includes proteins, carbohydrates, fats, nutrients, and seasonings.
  • a natural carbohydrate or flavoring agent can be included as an additional ingredient.
  • the natural carbohydrate is preferably a monosaccharide (e.g., glucose, fructose, etc.), a disaccharide (e.g., maltose, sucrose, etc.), an oligosaccharide, a polysaccharide (e.g., dextrin, cyclodextrin, etc.), or a sugar alcohol (e.g., xylitol, sorbitol, erythritol, etc.).
  • the flavoring agent can be a natural flavoring agent (e.g., thaumatin, stevia extract, etc.) or a synthetic flavoring agent (e.g., saccharin, aspartame, etc.).
  • various nutrients, vitamins, electrolytes, flavoring agents, coloring agents, pectic acid and its salts, alginic acid and its salts, organic acids, protective colloid thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohol, carbonating agents used in carbonated beverages, etc. may be further contained.
  • the ratio of these added components is not particularly important, but is generally selected within the range of 0.01 to 0.1 parts by weight per 100 parts by weight of the health functional food composition of the present invention.
  • the present invention relates to a feed additive for improving memory containing an extract of Galium odoratum as an effective ingredient.
  • the feed additive of the present invention corresponds to supplementary feed under the Feed Management Act.
  • the term "feed” in the present invention may mean any natural or artificial diet, meal, etc., or ingredients of the meal, which are intended for or suitable for animals to eat, ingest, and digest.
  • the type of the feed is not particularly limited, and feed commonly used in the relevant technical field may be used.
  • Non-limiting examples of the feed include plant feeds such as grains, roots, fruits, food processing by-products, algae, fibers, pharmaceutical by-products, oils and fats, starches, meal, or grain by-products; and animal feeds such as proteins, inorganic substances, oils and fats, mineral substances, oils and fats, single-cell proteins, zooplankton, or food. These may be used alone or in combination of two or more.
  • the present invention relates to a herbal medicine composition for preventing or treating cognitive dysfunction containing an extract of Galium odoratum as an active ingredient.
  • the herbal medicine composition according to the present invention refers to a conventional dried medicinal herb form used in the manufacture of herbal medicine.
  • the herbal medicine composition of the present invention may be an extract obtained by extracting a solvent selected from water, C1 - C4 lower alcohols, or mixtures thereof according to a conventional method, or may be an extract in powder form obtained by drying the extract, and there are no particular restrictions on the formulation. For example, it may be manufactured in the form of a pill, tablet, capsule, or liquid.
  • the present invention relates to a veterinary composition for preventing or treating cognitive dysfunction containing an extract of Galium odoratum as an active ingredient.
  • the veterinary composition of the present invention may further comprise suitable excipients and diluents according to conventional methods.
  • Excipients and diluents that may be included in the veterinary composition of the present invention include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia gum, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, cetanol, stearyl alcohol, liquid paraffin, sorbitan monostearate, polysorbate 60, methylparaben, propylparaben, and mineral oil.
  • the veterinary composition according to the present invention may further include fillers, anticoagulants, lubricants, wetting agents, flavoring agents, emulsifiers, preservatives, etc., and the veterinary composition according to the present invention may be formulated using a method well known in the art so as to provide rapid, sustained or delayed release of the active ingredient after administration to an animal, and the formulation may be in the form of powders, granules, tablets, capsules, suspensions, emulsions, solutions, syrups, aerosols, soft or hard gelatin capsules, suppositories, sterile injectable solutions, sterile topical preparations, etc.
  • the effective amount of the veterinary composition according to the present invention may be appropriately selected depending on the individual animal.
  • the extract was placed in a 100°C water heater for 3 hours, filtered through a Buchner funnel with filter paper placed on it, and the filtrate was filtered under reduced pressure, freeze-dried to obtain a powdered sedge hot water extract.
  • the hippocampus which is responsible for cognitive function, was isolated from the mouse brain and used for experiments.
  • the isolated hippocampal neurons were seeded into 96-well plates and stabilized for 24 hours. They were then pretreated with extracts of sagebrush leaves or whole plant (hereinafter referred to as "samples") and cultured for 24 hours. The samples were then co-treated with 5 mM glutamate, which induces neuronal damage. After 24 hours, cell viability was determined using an MTT assay. All data were analyzed using GraphPad Prism 5, and statistical significance was assessed using ANOVA and Tukey's post hoc test to compare multiple groups. A p value less than 0.05 was considered statistically significant.
  • the cell viability was significantly reduced in the glutamate-only treatment group compared to the normal group (Con), and the cell viability was increased in the scutellaria root extract treatment group of the present invention compared to the glutamate treatment group. From these results, it was determined that the scutellaria root extract of the present invention had a cell protective effect.
  • the group treated with the 70% (v/v) ethanol extract of scutellaria root showed a statistically significant increase in cell viability in the concentration range of 5 to 100 ⁇ g/ml, and the group treated with the hot water extract of scutellaria root showed a statistically significant increase in cell viability in the concentration range of 10 to 50 ⁇ g/ml.
  • the cognitive impairment animal model in Example 3 means that learning ability and memory are impaired.
  • mice Seven-week-old mice were purchased and stabilized for one week before use in the experiment. 50 mg/kg of GO-E and GO-W dissolved in drinking water were orally administered to the mice for 7 days, after which scopolamine and the ethanol and water extracts of GO-W were administered simultaneously and injected.
  • the normal group (Con) was administered drinking water and saline, and the control group (SCO) was administered drinking water and scopolamine.
  • 1 mg/kg of donepezil (positive control) was dissolved in drinking water and administered together with scopolamine.
  • mice were treated with Y-shaped plastic passages at a 120° angle to each other.
  • the time spent in a new space in the Y maze space of the scopolamine-administered group (SCO) was statistically significantly reduced compared to the normal control group (CON), and in contrast, the time spent in a new space of the group administered the sedge extract of the present invention was statistically significantly increased.
  • mice were placed in a Y-maze and allowed to freely explore for 10 minutes. Each arm entry was recorded, and the behavioral tendency to alternate between the three arms was analyzed. This experiment capitalized on animals' natural tendency to explore, exploring each arm instead of returning to the same arm.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Polymers & Plastics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Food Science & Technology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hospice & Palliative Care (AREA)
  • Physiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Husbandry (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

La présente invention concerne une composition pour améliorer la mémoire et prévenir, soulager ou traiter une déficience cognitive, la composition contenant un extrait de galium odoratum en tant que principe actif. L'extrait de galium odoratum de la présente invention présente un excellent effet protecteur des cellules nerveuses, et a montré les effets d'amélioration de la mémoire et d'amélioration de la capacité d'apprentissage dans une expérience de labyrinthe en Y en utilisant un modèle animal présentant une fonction cognitive réduite. Par conséquent, l'extrait de galium odoratum peut être avantageusement utilisé en tant que médicament ou aliment fonctionnel de santé pour prévenir, soulager ou traiter une déficience cognitive par l'amélioration de la capacité d'apprentissage ou de la mémoire.
PCT/KR2025/006160 2024-05-09 2025-05-08 Composition pour améliorer la mémoire et prévenir, soulager ou traiter une déficience cognitive, contenant un extrait de galium odoratum en tant que principe actif Pending WO2025234773A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020240061292A KR20250161898A (ko) 2024-05-09 2024-05-09 선갈퀴 추출물을 유효성분으로 포함하는 기억력 증진 및 인지기능 장애의 예방, 개선 또는 치료용 조성물
KR10-2024-0061292 2024-05-09

Publications (1)

Publication Number Publication Date
WO2025234773A1 true WO2025234773A1 (fr) 2025-11-13

Family

ID=97675530

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2025/006160 Pending WO2025234773A1 (fr) 2024-05-09 2025-05-08 Composition pour améliorer la mémoire et prévenir, soulager ou traiter une déficience cognitive, contenant un extrait de galium odoratum en tant que principe actif

Country Status (2)

Country Link
KR (1) KR20250161898A (fr)
WO (1) WO2025234773A1 (fr)

Also Published As

Publication number Publication date
KR20250161898A (ko) 2025-11-18

Similar Documents

Publication Publication Date Title
WO2019124863A1 (fr) Composition contenant comme principe actif un extrait de feuilles de schisandra chinensis destinée à la prévention, à l'amélioration et au traitement de la dermatite atopique
WO2016186349A2 (fr) Composition, contenant un extrait de quisaqualis indica, pour la prévention ou le traitement de l'hyperplasie prostatique
WO2016190566A9 (fr) Composition pharmaceutique ou aliment naturel fonctionnel pour la prévention et le traitement de maladies métaboliques, contenant un extrait aqueux de pleurotus eryngii var. ferulae (pf.) en tant que principe actif
WO2018080157A1 (fr) Composition pour la prévention, le soulagement ou le traitement d'un déficit cognitif, contenant un extrait de ficus erecta en tant que principe actif
WO2025234773A1 (fr) Composition pour améliorer la mémoire et prévenir, soulager ou traiter une déficience cognitive, contenant un extrait de galium odoratum en tant que principe actif
WO2018008973A1 (fr) Composition comprenant un extrait de forsythiae fructus en tant que principe efficace pour prévenir, améliorer ou traiter la neuropathie périphérique
WO2019083264A1 (fr) Composition pour prévenir, soulager ou traiter des maladies du foie, contenant un produit fermenté d'extrait de germe de ginseng vieilli en tant que substance active
KR102711959B1 (ko) 송악 잎 추출물을 유효성분으로 함유하는 인지기능 또는 기억력 개선용 조성물
KR102649776B1 (ko) 백출 및 수영 추출물의 복합물을 유효성분으로 포함하는 기억력 증진 및 인지기능장애의 예방, 개선 또는 치료용 조성물
WO2021085741A1 (fr) Composition d'amélioration ou de traitement de la maladie d'alzheimer comprenant comme principe actif du tetragonia tetragonioides
KR20220017072A (ko) 익모초 추출물 및 박하 추출물의 복합 추출물을 유효성분으로 포함하는 인지기능장애 예방 또는 치료용 조성물
KR102894064B1 (ko) It104489, it221621 및 it320916 품종의 수수 추출물을 유효성분으로 함유하는 위암의 예방, 개선 또는 치료용 조성물
WO2023249280A1 (fr) Composition pour améliorer la mémoire et prévenir, soulager ou traiter une déficience cognitive contenant du yuk-gunja-tang en tant que principe actif
WO2012108744A2 (fr) Composition et alimentation fonctionnelle pour traiter le cancer du cerveau comprenant un extrait de la fleur inula
KR102763559B1 (ko) 금전초 추출물을 유효성분으로 포함하는 장질환의 예방, 개선 또는 치료용 조성물
KR102715990B1 (ko) 말벌 추출물을 유효성분으로 함유하는 당뇨병의 예방 또는 치료용 약학적 조성물 및 건강 기능 식품
WO2024191115A1 (fr) Composition pour la prévention, l'amélioration ou le traitement de maladies gastro-intestinales, comprenant un extrait de cucumis melo l. en tant que principe actif
WO2024253387A2 (fr) Composition pour améliorer la mémoire et prévenir, soulager ou traiter une déficience cognitive, contenant un extrait d'orixa japonica en tant que principe actif
WO2023204363A1 (fr) Composition pour prévenir, améliorer ou traiter la dermatite atopique comprenant un extrait d'alpinia officinarum hance en tant que principe actif
WO2024117770A1 (fr) Composition comprenant un extrait de riz coloré en tant que principe actif pour améliorer l'immunité
WO2023224305A1 (fr) Composition destinée à prévenir, atténuer ou traiter l'arthrite et la douleur articulaire, comprenant comme principe actif un extrait de lysimachia mauritiana
WO2025110273A1 (fr) Composition pour prévenir, soulager ou traiter un dysfonctionnement cognitif, contenant un extrait d'oxya chinensis sinuosa en tant que principe actif
WO2023243855A1 (fr) Composition comprenant un extrait de daihong crataegus pinnatifida bunge en tant que principe actif pour améliorer la santé intestinale ou traiter une maladie intestinale inflammatoire
WO2024106846A1 (fr) Composition comprenant un extrait de suaeda glauca en tant que principe actif pour la prévention, le soulagement ou le traitement d'une maladie hépatique
KR20250031435A (ko) 한련초 추출물을 유효성분으로 함유하는 천포창의 예방, 개선 또는 치료용 조성물